rs28897701
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs41293521
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs4987046
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs56070345
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs587781803
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80358479
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80358981
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs80359078
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80359176
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs80359477
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The subgroup analysis for serous cancer subgroup showed that the significant association could be detected under recessive model (OR = 1.38, 95% CI, 1.01-1.89, P = 0.04) and under homozygote comparison (OR = 1.46, 95% CI, 1.06-2.01, P = 0.022).Our meta-analysis suggests that the N372H polymorphism is associated with susceptibility of ovarian cancer.
|
26496279 |
2015 |
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Moreover, stratified analyses by the cancer type and source of control observed significantly increased risk associated with BRCA2 N372H in subgroups with ovarian cancer, non-Hodgkin lymphoma and population-based controls, but not breast cancer or hospital-based controls.
|
25348552 |
2014 |
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The HH genotype of the nonconservative amino acid substitution polymorphism N37</span>2H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer.
|
15668505 |
2005 |
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We have examined whether BRCA2 N372</span>H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer.
|
14555511 |
2003 |
rs11571833
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer.
|
29767749 |
2018 |
rs11571833
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10(-) (6)) and invasive ovarian cancer</span> (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10(-3)).
|
26586665 |
2016 |
rs876658943
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association between BRCA2 Arg372His polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) appropriately derived from fixed effects models.
|
26111274 |
2015 |
rs55854959
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
|
20437199 |
2010 |
rs80358721
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation.
|
19654294 |
2009 |